Loading...
克里唑替尼治疗晚期非小细胞肺癌的临床研究进展
At present, in the treatment of non-small cell lung cancer (NSCLC), targeted therapy has an important status. After epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs), crizotinib targeted at EML4-ALK fusion gene becomes a significant drug of molecular targeted therapy in NSCLC. P...
Na minha lista:
| Udgivet i: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
中国肺癌杂志编辑部
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000565/ https://ncbi.nlm.nih.gov/pubmed/23769348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.09 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|